Liver cirrhosis in metabolic dysfunction-associated steatohepatitis

Authors

Donghyun Ko, Department of Internal Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, CT, USA.
Do Han Kim MD, Department of Medicine, Mount Sinai Morningside and West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
Pojsakorn Danpanichkul, Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Masahito Nakano, Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Chitachai Rattananukrom, Division of Gastroenterology and Hepatology, Department of Medicine, Faculty of Medicine, Srinagarind Hospital, Khon Kaen University, Khon Kaen, Thailand.
Karn Wijarnpreecha, Department of Internal Medicine, Bassett Medical Center, Cooperstown, New York, USA.
Cheng Han NG, Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan; Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital Singapore, Singapore.
Mark D. Muthiah, Division of Gastroenterology and Hepatology, Department of Medicine, National University Hospital Singapore, Singapore. Electronic address: mdcmdm@nus.edu.sg.

Document Type

Article

Publication Title

Gastroenterology Report

Abstract

In the present narrative review, we have summarized the current evidence on the natural progression of metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis observed through the placebo arm in clinical trials and observational studies. The outcomes scrutinized throughout our review were histology-related changes, non-invasive fibrosis markers, indicators of decompensation, end-stage hepatic complications, and mortality reported during the different clinical trials. Given the short duration of clinical trials, observational studies were included to obtain better insight into the long-term progression and prognosis of MASH cirrhosis. Lastly, new updates about MASH cirrhosis treatments were listed, and the results of these randomized clinical trials were described to enhance our understanding of our current standing in the treatment of MASH cirrhosis.

DOI

10.1093/gastro/goaf037

Publication Date

5-2-2025

Comments

M.D.M. has served as a consultant to Roche, Estella, and Gilead. He has been an advisor for Lerna Bio. M.D.M. has received payment from speaking at Boston Scientific, Olympus Medical, Roche, and Astellas. M.D.M. is supported by the Singapore Ministry of Health through the National Medical Research Council (NMRC) Office, MOH Holdings Pte Ltd under the NMRC Clinician Scientist-Individual Research Grant (MOH-001228) and NMRC Clinician Scientist Award (MOH-001631), as well as the National Research Foundation, Singapore (NRF) under the NMRC Open Fund–Large Collaborative Grant (MOH-001325) and administered by the Singapore Ministry of Health through the NMRC Office, MOH Holdings Pte Ltd. C.H.N. consulted for Boxer Capital.

Recommended Citation

Ko D, Kim DH, Danpanichkul P, Nakano M, Rattananukrom C, Wijarnpreecha K, Ng CH, Muthiah MD. Liver cirrhosis in metabolic dysfunction-associated steatohepatitis. Gastroenterol Rep (Oxf). 2025 May 2;13:goaf037. doi: 10.1093/gastro/goaf037.

e-ISSN

2052-0034